Dec 03, 2024
Resalis Therapeutics Announces Initiation of Phase 1 Clinical Trial for RES-010 in Obesity
Dec 03, 2024
Resalis Therapeutics Announces Initiation of Phase 1 Clinical Trial for RES-010 in Obesity
Feb 1, 2024
Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer
Jan 4, 2024
Resalis Therapeutics Raises €10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity
Feb 22, 2023
Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases